Comparison of efficacy and safety of different dosages of mifepristone in women with symptomatic fibroids.

Department of obstetrics and gynaecology0 个研究点目标入组 92 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Symptomatic fibroid cases, measuring at least 3 cm exhibiting heavy menstrual bleeding or dysmenorrhoea or pelvic pressure 2.Those giving consent
•3.Accepting the use of non-hormonal contraceptive
•4.Agreeing to endometrial biopsy if needed

•1.currently planning pregnancy during study period
•2.menopausal
•3.currently breastfeeding
•4.adnexal mass or endometriosis
•5. coagulation dysfunction or bleeding tendencies
•6.severe anemia <5 g% or needing blood transfusion
•7.current or recent (within 3 months) use of oral / systemic corticosteroids or mifepristone
•8.use within past 6 months of GnRH analogues
•9.any contraindication to receive anti-progestins
•10.any history or suspicion of breast cancer or other genital malignancy
•11.laboratory findings that give any suspicion of blood, liver or renal dysfunction
•12.those not giving consent

发起方

Department of obstetrics and gynaecology